CN
Search Within
PHR1437
Applied Filters:
Keyword:'PHR1437'
Showing 1-30 of 48 results for "PHR1437" within Papers
Yun-Yu Chen et al.
Translational oncology, 14(1), 100897-100897 (2020-10-18)
Zinc(II)-dipicolylamine (Zn-DPA) has been shown to specifically identify and bind to phosphatidylserine (PS), which exists in bulk in the tumor microenvironment. BPRDP056, a Zn-DPA-SN38 conjugate was designed to provide PS-targeted drug delivery of a cytotoxic SN38 to the tumor microenvironment
Ning Yang et al.
Journal of translational medicine, 12, 278-278 (2014-10-05)
Although several studies suggest that stromal fibroblasts mediate treatment resistance in several cancer types, little is known about how tumor-associated astrocytes modulate the treatment response in brain tumors. Since traditionally used metabolic assays do not distinguish metabolic activity between stromal
Dawn Q Chong et al.
BMC cancer, 15, 255-255 (2015-04-18)
The treatment of glioblastoma multiforme (GBM) is an unmet clinical need. The 5-year survival rate of patients with GBM is less than 3%. Temozolomide (TMZ) remains the standard first-line treatment regimen for gliomas despite the fact that more than 90%
Julie Sesen et al.
PloS one, 10(4), e0123721-e0123721 (2015-04-14)
High-grade gliomas, glioblastomas (GB), are refractory to conventional treatment combining surgery, chemotherapy, mainly temozolomide, and radiotherapy. This highlights an urgent need to develop novel therapies and increase the efficacy of radio/chemotherapy for these very aggressive and malignant brain tumors. Recently
Georg Karpel-Massler et al.
Journal of neuro-oncology, 122(1), 21-33 (2014-12-20)
The poor prognosis of patients with glioblastoma fuels the search for more effective therapeutic compounds. We previously hypothesised that the neuroleptic olanzapine may enhance antineoplastic effects of temozolomide the standard chemotherapeutic agent used in this disease. This study tested this
Jenny L Pokorny et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 21(8), 1916-1924 (2015-01-23)
Wee1 regulates key DNA damage checkpoints, and in this study, the efficacy of the Wee1 inhibitor MK-1775 was evaluated in glioblastoma multiforme (GBM) xenograft models alone and in combination with radiation and/or temozolomide. In vitro MK-1775 efficacy alone and in
Lauriane Goldwirt et al.
Journal of neuro-oncology, 122(2), 273-281 (2015-03-22)
Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Prognosis of GBM patients is poor with median overall survival around 15 months. Temozolomide is the chemotherapeutic agent used in the standard of care of newly diagnosed GBM
Hee-Yeon Cho et al.
Molecular cancer therapeutics, 13(8), 2004-2017 (2014-07-06)
Patients with glioblastoma multiforme (GBM), a malignant primary brain tumor, inevitably develop resistance to standard-of-care chemotherapy, temozolomide. This study explores the effects of the novel agent NEO212, a conjugate of temozolomide to perillyl alcohol, on temozolomide-resistant gliomas. NEO212 was tested
Navid Redjal et al.
Stem cells (Dayton, Ohio), 33(1), 101-110 (2014-09-05)
Despite advances in standard therapies, the survival of glioblastoma multiforme (GBM) patients has not improved. Limitations to successful translation of new therapies include poor delivery of systemic therapies and use of simplified preclinical models which fail to reflect the clinical
Ronald Koschny et al.
Journal of neuropathology and experimental neurology, 73(11), 1034-1046 (2014-10-08)
A meningioma is the most common primary intracranial tumor in adults. Here, we investigated the therapeutic potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in 37 meningiomas. Freshly isolated primary meningioma cells were treated with TRAIL with or without
Robert M Jotte et al.
Investigational new drugs, 33(1), 148-158 (2014-09-28)
This phase Ib study used a parallel, multi-arm design to examine tasisulam-sodium (hereafter tasisulam), a drug with complex pharmacology, combined with standard chemotherapies in patients with advanced solid tumors, with the ultimate goal of accelerating drug development. Patients received escalating
Yuichi Miki et al.
Photodiagnosis and photodynamic therapy, 11(4), 556-564 (2014-09-30)
Photodynamic therapy (PDT) induces selective cell death of neoplastic tissue and connecting vasculature by combining photosensitizers with light. We have previously reported that PDT induces apoptotic cell death in glioma cells when the photosensitizer talaporfin sodium (NPe6) is used. Here
David B Rosen et al.
Journal of translational medicine, 12, 184-184 (2014-06-27)
Homologous recombination repair (HRR) pathway deficiencies have significant implications for cancer predisposition and treatment strategies. Improved quantitative methods for functionally characterizing these deficiencies are required to accurately identify patients at risk of developing cancer and to identify mechanisms of drug
Kamila Wojciechowicz et al.
Gastroenterology, 147(5), 1064-1072 (2014-08-05)
Lynch syndrome, a nonpolyposis form of hereditary colorectal cancer, is caused by inherited defects in DNA mismatch repair (MMR) genes. Most patients carry a germline mutation in 1 allele of the MMR genes MSH2 or MLH1. With spontaneous loss of
Amar Desai et al.
DNA repair, 21, 55-64 (2014-07-20)
Functional DNA mismatch repair (MMR) is essential for maintaining the fidelity of DNA replication and genetic stability. In hematopoiesis, loss of MMR results in methylating agent resistance and a hematopoietic stem cell (HSC) repopulation defect. Additionally MMR failure is associated
Zhumei Shi et al.
Neuro-oncology, 16(10), 1341-1353 (2014-05-28)
Glioma is one of the most aggressive and lethal human brain tumors. Accumulating evidence shows that microRNAs play important roles in cancers, including glioma. Previous studies reported that miR-124 levels were downregulated in glioma specimens. Here, we further investigate the
Qiao Liu et al.
Molecular cancer therapeutics, 14(2), 355-363 (2014-12-17)
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor and has a poor prognosis. We, here, report a potent antitumor effect of berberine, an isoquinoline alkaloid, on GBM. Berberine was found to have an IC50 that is much
Annette Wilisch-Neumann et al.
Journal of cancer research and clinical oncology, 140(8), 1343-1352 (2014-05-13)
The purpose was to re-evaluate in cell culture models the therapeutic usefulness of some discussed chemotherapies or targeted therapies for meningiomas with a special emphasis on the role of the neurofibromatosis type 2 (NF2) tumor suppressor, which had been neglected
Sharmistha Chakraborty et al.
Nature communications, 5, 5811-5811 (2014-12-17)
Epidermal growth factor receptor (EGFR) overexpression plays an important oncogenic role in cancer. Regular EGFR protein levels are increased in cancer cells and the receptor then becomes constitutively active. However, downstream signals generated by constitutively activated EGFR are unknown. Here
Lauriane Goldwirt et al.
Cancer chemotherapy and pharmacology, 74(1), 185-193 (2014-05-29)
Glioblastoma (GBM), the most common primary brain tumor in adults, is usually rapidly fatal with median survival duration of only 15 months and a 3-year survival rate of <7 %. Temozolomide (TMZ) is the only anticancer drug that has improved
Sara Gm Piccirillo et al.
Cancer research, 75(1), 194-202 (2014-11-20)
Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the sub-ependymal zone (SEZ) of patients with glioblastoma. Histologic analysis and genomic characterization revealed
Alfeu Zanotto-Filho et al.
Cancer letters, 358(2), 220-231 (2014-12-30)
Glioblastoma is a devastating primary brain tumor resistant to conventional therapies. In this study, we tested the efficacy of combining temozolomide with curcumin, a phytochemical known to inhibit glioblastoma growth, and investigated the mechanisms involved. The data showed that synergy
Reshma Rangwala et al.
Autophagy, 10(8), 1369-1379 (2014-07-06)
Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of HCQ in combination with dose-intense temozolomide (TMZ) in
Tae-Young Jung et al.
Journal of neuro-oncology, 121(2), 413-419 (2014-11-05)
We analyzed the prognostic factors of Korean pediatric patients with supratentorial high-grade glioma (HGG). Between 1997 and 2011, 62 patients with 34 glioblastomas and 28 anaplastic gliomas were surgically operated at nine institutions. The male-to-female ratio was 33 to 29
Stephanie A Nguyen et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(18), 4894-4903 (2014-08-01)
The current standard of care for glioblastoma (GBM) involves a combination of surgery, radiotherapy, and temozolomide chemotherapy, but this regimen fails to achieve long-term tumor control. Resistance to temozolomide is largely mediated by expression of the DNA repair enzyme MGMT;
Yolande Berthois et al.
Cancer biology & therapy, 15(7), 938-950 (2014-04-24)
Glioblastoma multiforme (GBM) is the most common primary brain tumor and is among the deadliest of human cancers. Dysregulation of microRNAs (miRNAs) expression is an important step in tumor progression as miRNAs can act as tumor suppressors or oncogenes and
Diane Palmieri et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(10), 2727-2739 (2014-03-19)
Brain metastases of breast cancer cause neurocognitive damage and are incurable. We evaluated a role for temozolomide in the prevention of brain metastases of breast cancer in experimental brain metastasis models. Temozolomide was administered in mice following earlier injection of
Kit Man Chai et al.
Oncotarget, 5(21), 10901-10915 (2014-10-23)
We previously found that BRCA1-BRCA2-containing complex subunit 3 (BRCC3) was highly expressed in tumorigenic rat glioma cells. However, the functional role of BRCC3 in human glioma cells remains to be characterized. This study indicated that the upregulation of BRCC3 expression
Junya Fukai et al.
PloS one, 9(8), e104538-e104538 (2014-08-12)
Temozolomide (TMZ), a DNA methylating agent, is widely used in the adjuvant treatment of malignant gliomas. O6-methylguanine-DNA methyltranferase (MGMT), a DNA repair enzyme, is frequently discussed as the main factor that limits the efficacy of TMZ. Zoledronic acid (ZOL), which
Sameer Agnihotri et al.
Cancer discovery, 4(10), 1198-1213 (2014-08-08)
Alkylating agents are a first-line therapy for the treatment of several aggressive cancers, including pediatric glioblastoma, a lethal tumor in children. Unfortunately, many tumors are resistant to this therapy. We sought to identify ways of sensitizing tumor cells to alkylating
Page 1 of 2